Effects of obesity on bone metabolism.
Cao JJ. · 2011
Read Effects of obesity on bone metabolism. by Cao JJ. (2011) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc3141563.txt.
Introduction
Jay Cao reviewed how excess weight affects bones in a 2011 paper in the Journal of Orthopaedic Surgery and Research. Heavy bodies load the skeleton, which should build bone, so obesity was long seen as protecting against brittle bones. Newer population and animal studies, though, point the other way, linking fat gain to lower bone mass.
Several routes may explain the harm. Fat and bone cells share a parent cell type, so fat gain can divert building away from bone. The chronic inflammation of obesity stokes bone-eating cells, fat hormones act directly on bone balance, and fatty diets can block calcium uptake from food. Untangling these paths, Cao argues, could yield drugs that treat weight and bone loss together.
Catalog record
| CREATOR | Cao JJ. |
|---|---|
| YEAR | 2011 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 37 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Effects of obesity on bone metabolism By Jay J Cao Published in: Journal of Orthopaedic Surgery and Research DOI: 10.1186/1749-799X-6-30 ABSTRACT Obesity is traditionally viewed to be beneficial to bone health because of well-established positive effect of mechanical loading conferred by body weight on bone formation, despite being a risk factor for many other chronic health disorders. Although body mass has a positive effect on bone formation, whether the mass derived from an obesity condition or excessive fat accumulation is beneficial to bone remains controversial. The underline pathophysiological relationship between obesity and bone is complex and continues to be an active research area. Recent data from epidemiological and animal studies strongly support that fat accumulation is detrimental to bone mass. To our knowledge, obesity possibly affects bone metabolism through several mechanisms. Because both adipocytes and osteoblasts are derived from a common multipotential mesenchymal stem cell, obesity may increase adipocyte differentiation and fat accumulation while decrease osteoblast differentiation and bone formation. Obesity is associated with chronic inflammation. The increased circulating and tissue proinflammatory cytokines in obesity may promote osteoclast activity and bone resorption through modifying the receptor activator of NF-κB (RANK)/RANK ligand/osteoprotegerin pathway. Furthermore, the excessive secretion of leptin and/or decreased production of adiponectin by adipocytes in obesity may either directly affect bone formation or indirectly affect bone resorption through up-regulated proinflammatory cytokine production. Finally, high-fat intake may interfere with intestinal calcium absorption and therefore decrease calcium availability for bone formation. Unraveling the relationship between fat and bone metabolism at molecular level may help us to develop therapeutic agents to prevent or treat both obesity and osteoporosis. Obesity, defined as having a body mass index ≥ 30 kg/m2, is a condition in which excessive body fat accumulates to a degree that adversely affects health [1]. The rates of obesity rates have doubled since 1980 [2] and as of 2007, 33% of men and 35% of women in the US are obese [3]. Obesity is positively associated to many chronic disorders such as hypertension, dyslipidemia, type 2 diabetes mellitus, coronary heart disease, and certain cancers [4-6]. It is estimated that the direct medical cost associated with obesity in the United States is ~$100 billion per year [7]. Bone mass and strength decrease during adulthood, especially in women after menopause [8]. These changes can culminate in osteoporosis, a disease characterized by low bone mass and microarchitectural deterioration resulting in increased bone fracture risk. It is estimated that there are about 10 million Americans over the age of 50 who have osteoporosis while another 34 million people are at risk of developing the disease [9]. In 2001, osteoporosis alone accounted for some $17 billion in direct annual healthcare expenditure. Several lines of evidence suggest that obesity and bone metabolism are interrelated. First, both osteoblasts (bone forming cells) and adipocytes (energy storing cells) are derived from a common mesenchymal stem cell [10] and agents inhibiting adipogenesis stimulated osteoblast differentiation [11-13] and vice versa, those inhibiting osteoblastogenesis increased adipogenesis [14]. Second, decreased bone marrow osteoblastogenesis with aging is usually accompanied with increased marrow adipogenesis [15,16]. Third, chronic use of steroid hormone, such as glucocorticoid, results in obesity accompanied by rapid bone loss [17,18]. Fourth, both obesity and osteoporosis are associated with elevated oxidative stress and increased production of proinflammatory cytokines [19,20]. At present, the mechanisms for the effects of obesity on bone metabolism are not well defined and will be the focus of this review. PROINFLAMMATORY CYTOKINES ARE ELEVATED IN OBESITY Obesity is associated with low-grade chronic inflammation. The seminal finding that the expression of a proinflammatory cytokine, tumor necrosis factor-α (TNF-α), is elevated in the adipose tissue of obese mice provided the first evidence of a link between obesity and inflammation [21]. Later, the discovery of leptin, a small polypeptide hormone secreted primarily by the adipocytes, further supports that adipose is not just a energy storing organ and it is also an active endocrine tissue [22,23]. Since then, numerous experimental, epidemiological, and clinical studies have established that obesity is associated with a chronic inflammatory response, abnormal cytokine production, increased acute-phase reactants, and activation of inflammatory signaling pathways, and that these processes are involved in and responsible for the development of obesity-related diseases [24]. In obesity, adipose tissue is infiltrated with an increased amount of macrophages, which are an important source of inflammatory cytokines [25,26]. Obese humans express higher levels of TNF-α in adipose tissue than do lean individuals [27]. Adipose tissue also produces other proinflammatory factors including interlukin-6 (IL-6) and C-reactive protein (CRP) [28,29]. Obesity has also been implicated in the development or progression of musculoskeletal diseases such as osteoarthritis, a common inflammatory bone disease [30]. Numerous studies have confirmed that increased production of proinflammatory cytokines are critical in the development and progression of obesity-related health disorders [31]. Obese individuals show abnormal circulating levels of TNF-α, IL-6, CRP, adiponectin and leptin. Adiponectin and leptin, which also mediate chronic inflammation, are adipokines produced by adipose tissue. Leptin has pleiotropic effects that modulate energy expenditure, appetite, and neuroendocrine functions. Leptin, which is increased in obesity, has been found to stimulate inflammatory responses in humans [32,33]. In contrast adiponectin acts as an anti-inflammatory cytokine which suppresses TNF-α-induced NF-κB activation [34]. It has been found that plasma adiponectin concentrations are lower in obese subjects as compared to non-obese individuals [35]. In a cross-sectional study of 16,573 individuals in the third National Health and Nutrition Examination Survey (NHANES) (1984-1994), logistic regression analysis showed that odds ratios for an elevated serum CRP among individuals with a body mass index (BMI) of 25- < 30, 30- < 35, 35- < 40, and ≥40 were 1.51, 3.9, 6.11, and 9.30, respectively [36]. In another cross-sectional study, CRP, IL-6 and leptin were significantly positively related to degree of adiposity [37]. PROINFLAMMATORY CYTOKINES INCREASE BONE RESORPTION Bone is a dynamic organ that continuously undergoes significant turnover, a process called modeling/remodeling involving bone resorption by osteoclasts and bone formation by osteoblasts [38]. Therefore, bone mass at any particular time reflects the balance between bone formation and resorption. At the cellular level, osteoblast number and activity decrease while osteoclast number and activity increase with aging [39,40]. It is now established that osteoblasts regulate the recruitment and activity of osteoclasts through the expression of the receptor activator of NF-κB ligand (RANKL) and osteoprotegerin (OPG) (Figure 1). RANKL is expressed on the osteoblast/stromal cell surface and binds to its receptor, RANK, on the surface of hematopoietic precursor cells to stimulate osteoclast differentiation and maturation in the presence of macrophage colony stimulation factor (M-CSF). OPG, a decoy receptor secreted by osteoblasts, binds RANKL to prevent the activation of RANK and, therefore, to prevent osteoclast differentiation and activation [41,42]. It has been demonstrated that increased osteoclastic activity and increased bone resorption in postmenopausal women is positively correlated with the upregulation of RANKL [39,43,44]. [Figure: Bone metabolism regulated by adipocytes, osteoblasts, and osteoclasts. Fat accumulation is closely related to bone formation and resorption. Osteoblasts and adipocytes are derived from a common multipotential mesenchymal stem cell. Osteoclasts are differentiated from monocyte/macrophage precursors of hematopoietic stem cells origin. Adipocytes secrete several cytokines such as TNF-α, IL-1β, IL-6, adiponectin, and leptin which are capable of modulating osteoclastogenesis through RANKL/RANK/OPG pathway.IL, interleukin; OPG, osteoprotegerin; RANK, receptor